$Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma$

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL),...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2011-03, Vol.29 (9), p.1198-1203
Hauptverfasser:	KIRSCHBAUM, Mark, FRANKEL, Paul, NADEMANEE, Auayporn, FORMAN, Stephen J, GANDARA, David, NEWMAN, Edward, POPPLEWELL, Leslie, ZAIN, Jasmine, DELIOUKINA, Maria, PULLARKAT, Vinod, MATSUOKA, Deron, PULONE, Bernadette, ROTTER, Arnold J, ESPINOZA-DELGADO, Igor
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic Agents - therapeutic use Biological and medical sciences Drug Resistance, Neoplasm - drug effects Female Hematologic and hematopoietic diseases Humans Hydroxamic Acids - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell, Marginal Zone - drug therapy Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, Follicular - drug therapy Lymphoma, Follicular - pathology Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - pathology Male Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Original Reports Remission Induction Salvage Therapy Survival Rate Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!